All Stories

  1. Sphingosine kinase 1–interacting protein is a dual regulator of insulin and incretin secretion

    Article • The FASEB Journal, February 2019, Wiley

    Shin-ichi Harashima, YANYAN LIU, Daisuke Tanaka, Dr Daisuke Yabe

  2. Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients

    Article • Expert Opinion on Pharmacotherapy, May 2018, Taylor & Francis

    Shin-ichi Harashima

  3. SMBG-OHA Follow-Up Study

    Article • Journal of Diabetes Science and Technology, October 2015, SAGE Publications

    Shin-ichi Harashima

  4. Efficacy and Safety of Switching from Basal Insulin to Sitagliptin in Japanese Type 2 Diabetes Patients

    Article • Hormone and Metabolic Research, September 2012, Thieme Publishing Group

    Shin-ichi Harashima